Phibro Animal Health Corporation Stock

Equities

PAHC

US71742Q1067

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
13.04 USD +1.32% Intraday chart for Phibro Animal Health Corporation -0.38% +12.61%
Sales 2024 * 998M Sales 2025 * 1.03B Capitalization 528M
Net income 2024 * 15M Net income 2025 * 28M EV / Sales 2024 * 0.83 x
Net Debt 2024 * 301M Net Debt 2025 * 297M EV / Sales 2025 * 0.8 x
P/E ratio 2024 *
35.2 x
P/E ratio 2025 *
18.4 x
Employees 1,920
Yield 2024 *
3.68%
Yield 2025 *
3.63%
Free-Float 49.9%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Phibro Animal Health Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 04:35 PM
Transcript : Phibro Animal Health Corporation Presents at Bank of America 2024 Animal Health Virtual Summit, Feb-29-2024 10:00 AM
Transcript : Phibro Animal Health Corporation, Q2 2024 Earnings Call, Feb 08, 2024
Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Posts Q2 EPS $0.33, vs. Street Est of $0.28 MT
Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Reports Q2 Revenue $249.9M, vs. Street Est of $240.9M MT
Phibro Animal Health Corporation Reaffirms Earnings Guidance for the Fiscal Year 2024 CI
Phibro Animal Health Corporation Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Phibro Animal Health Corporation Declares Quarterly Cash Dividend, Payable on March 27, 2024 CI
Phibro Animal Health Corporation Announces Chief Financial Officer Changes, Effective February 9, 2024 CI
Morgan Stanley Trims Price Target on Phibro Animal Health to $16 From $17, Maintains Equalweight Rating MT
Transcript : Phibro Animal Health Corporation, Q1 2024 Earnings Call, Nov 09, 2023
Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Reports Q1 EPS $0.14, vs. Street Est of $0.23 MT
Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Posts Q1 Revenue $231.3M, vs. Street Est of $242M MT
Phibro Animal Health Corporation Provides Consolidated Earnings Guidance for the Year Ending June 30, 2024 CI
Phibro Animal Health Corporation Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
More news
1 day+1.32%
1 week-0.38%
Current month+0.85%
1 month+4.49%
3 months+15.09%
6 months+7.68%
Current year+12.61%
More quotes
1 week
12.67
Extreme 12.67
13.40
1 month
12.07
Extreme 12.07
13.40
Current year
10.04
Extreme 10.035
13.92
1 year
9.40
Extreme 9.4
15.98
3 years
9.40
Extreme 9.4
31.00
5 years
9.40
Extreme 9.4
36.98
10 years
9.40
Extreme 9.4
54.62
More quotes
Managers TitleAgeSince
Chief Executive Officer 77 68-12-31
Director of Finance/CFO 52 Feb. 08
Chief Operating Officer 60 08-04-30
Members of the board TitleAgeSince
Chief Executive Officer 77 68-12-31
Director/Board Member 77 08-04-30
Director/Board Member 63 10-06-30
More insiders
Date Price Change Volume
24-04-18 13.04 +1.32% 78,597
24-04-17 12.87 -0.92% 99,784
24-04-16 12.99 -1.67% 139,846
24-04-15 13.21 +0.76% 146,143
24-04-12 13.11 +0.15% 120,894

Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT

More quotes
Phibro Animal Health Corporation is a diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 770 product lines in over 80 countries to approximately 4,000 customers. The Company has three segments. Animal Health segment develops, manufactures and markets about 270 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. Mineral Nutrition segment manufactures and markets approximately 420 formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries, predominantly in the United States.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
13.04 USD
Average target price
10.75 USD
Spread / Average Target
-17.56%
Consensus